Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2E1 | P05181 | 3/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.33 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.33 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25753271 | 0.88 | TLR8 (0.31) | — | |
| SCHEMBL22326854 | 0.87 | CYP2E1 (0.34) | CYP2E1CYP2A6CYP2B6CYP2C19CYP2C8 | |
| SCHEMBL26746936 | 0.87 | CDK1 (0.32) | — | |
| SCHEMBL25638688 | 0.86 | — | — | |
| SCHEMBL23502876 | 0.83 | TLR8 (0.34) | CYP2E1CYP2A6CYP2B6CYP2C19CYP2C8 | |
| SCHEMBL21308089 | 0.81 | CYP2E1 (0.35) | CYP2E1CYP2A6CYP2B6CYP2C19CYP2C8 | |
| SCHEMBL25753275 | 0.81 | ACACB (0.33) | — | |
| SCHEMBL23563318 | 0.80 | PGK1 (0.30) | — | |
| SCHEMBL16710430 | 0.80 | CYP2E1 (0.36) | CYP2E1CYP2A6CYP2B6CYP2C19CYP2C8 | |
| SCHEMBL17124955 | 0.79 | PNP (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203083-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-06-29 | — | — | US | disclosed |
| US-20230119408-A1 | NUCLEOTIDE ANALOGS AND USES THEREOF | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-04-20 | — | — | US | disclosed |
| US-20230028359-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-01-26 | — | — | US | disclosed |
| US-20220119779-A1 | MODIFIED PYROCOCCUS POLYMERASES AND USES THEREOF | FIRST-CITIZENS BANK & TRUST COMPANY | 2022-04-21 | — | — | US | disclosed |
| US-10738072-B1 | Nucleotide analogues | Singular Genomics Systems, Inc. (US) | 2020-08-11 | — | — | US | disclosed |
| US-9512163-B2 | Compositions and methods for conjugating oligonucleotides | AGILENT TECHNOLOGIES, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20150133631-A1 | Compositions and Methods for Conjugating Oligonucleotides | AGILENT TECHNOLOGIES, INC. | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230119408-A1 | NUCLEOTIDE ANALOGS AND USES THEREOF | NUDT1, PNP, NT5C2 | CYP2E1 3731/4885CYP2A6 1878/4885CYP2B6 1222/4885 |
| US-20230028359-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | CYP2E1 4109/4885CYP2A6 1541/4885CYP2B6 1379/4885 |
| US-10738072-B1 | Nucleotide analogues | NUDT1, POLN, TYMP | CYP2E1 3868/4885CYP2A6 1939/4885CYP2B6 1344/4885 |
| US-20150133631-A1 | Compositions and Methods for Conjugating Oligonucleotides | DCLRE1A, NR0B1, NR0B2 | CYP2E1 4111/4885CYP2A6 3951/4885CYP2B6 4023/4885 |
| US-20230203083-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | CYP2E1 4109/4885CYP2A6 1541/4885CYP2B6 1379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.